All In Biotech

Drug Trial Radar · NCT05244304

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Mar 28, 2022

Primary completion

Aug 4, 2025

Study completion Sep 11, 2025

Sponsor

Lead sponsor
Belite Bio, IncIndustry
Sponsor type
Industry
First posted
Feb 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1

Conditions

  • Stargardt Disease 1

Interventions

  • TinlarebantDrug

    Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.

  • PlaceboDrug

    Not active drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To measure change in atrophic lesion size (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baselineTime frame: Baseline thru month 24

Locations

19 sites in 11 countries. Site status is shown where the registry gives one.

  • Belite Study Site

    Palo Alto, California

  • Belite Study Site

    Minneapolis, Minnesota

  • Belite Study Site

    Salt Lake City, Utah

  • Belite Study Site

    South Brisbane, Australia

  • Belite Study Site

    Westmead, New South Wales, Australia

  • Belite Study Site

    East Melbourne, Victoria, Australia

  • Belite Study Site

    Ghent, Belgium

  • Belite Study Site

    Beijing, China

  • Belite Study Site

    Shanghai, China

  • Belite Study Site

    Paris, France

  • Belite Study Site

    Bonn, Germany

  • Belite Study Site

    Tübingen, Germany

  • Belite Study Site

    Kowloon, Hong Kong

  • Belite Study Site

    Nijmegen, Netherlands

  • Belite Study Site

    Basel, Switzerland

  • Belite Study Site

    Taipei, Taiwan

  • Belite Study Site

    Taoyuan City, Taiwan

  • Belite Study Site

    London, United Kingdom

  • Belite Study Site

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.